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Abstract
Background: γ-Hydroxybutyrate (GHB) is a drug of abuse with dose-dependent sedative effects. Systematic data on
the acute toxicity of GHB from emergency department (ED) presentations over a long period of time are currently
missing from the literature. The present study described the clinical features of GHB toxicity.
Methods: Retrospective case series of GHB intoxications seen in an urban ED.
Results: From January 2002 to September 2015, 78 GHB-related intoxication cases were recorded (71 % male
patients). The mean ± SD age was 29 ± 8 years. The co-use of alcohol and/or other illicit drugs was reported in 65 %
of the cases. Neurological symptoms other than central nervous system depression included agitation (40 %) and
clonus (21 %). The most frequent reasons for admission were coma (64 %) and agitation (23 %). The median time
to regain consciousness was 90 min (range, 3–400 min). Sudden recovery was reported in 25 cases (32 %). Coma
was not significantly associated with polyintoxication. Coma occurred in 77 % of the alcohol co-users and in 62 %
ofthe non-alcohol users (p=0.052). The mean recovery time in comatose patients was 142 min in patients with co-
use of alcohol compared with 89 min in patients without alcohol co-use (p=0.07). Alcohol co-use was not
significantly associated with nausea/vomiting (p=0.07). The co-use of stimulants was not significantly associated
with non-responsive coma (Glasgow Coma Scale = 3) or mean recovery time. Analytical confirmation of GHB was
available in 37 cases (47 %), with additional quantitative analysis in 20 cases. The median GHB concentration was
240 mg/L (range, 8.3–373 mg/L). Intoxication was severe in 72 % of the cases. No fatalities occurred, and 72 % of
the patients were discharged directly home from the ED.
Discussion: There were trend associations between alcohol co-use and frequency and length of coma and nausea/
vomiting which did not reach the significance level (all p=0.05-0.07) but may nevertheless be clinically relevant. As
the exact time of use is not always known, and co-use of other substances can affect the severity of poisoning, no
definitive conclusions can be drawn regarding the association between GHB concentration and severity.
Conclusion: Impaired consciousness and agitation were typical findings of GHB intoxication. The co-use of alcohol
and/or other illicit substances is common but was not significantly associated with the severity of the intoxications
in our study.
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Background
γ-Hydroxybutyrate (GHB), commonly known as “liquid ec-
stasy,” and its precursors γ-butyrolactone (GBL) and 1,4-
butanediol (BD) emerged as drugs of abuse in the early
1990s. Since that time, they have led to a greater burden on
healthcare providers [1–3]. After ingestion, GBL and BD
are rapidly converted to GHB, thereby producing the same
clinical effects [1, 3]. Throughout the present article, refer-
ence to GHB implicitly includes GBL and BD. GHB stimu-
lates GHB and γ-aminobutyric acid (GABA) receptors [4].
At lower doses, GHB produces mixed stimulant/sedative
effects, with a dose-dependent increase in sedation and diz-
ziness [5]. At higher doses, GHB can lead to severe coma,
cardiorespiratory depression, and death [1, 2, 6, 7]. There is
a non-linear dose-plasma concentration relationship, with
higher doses producing disproportionately higher plasma
exposure and a potentially high risk of overdose [5, 8, 9].
The plasma elimination half-life of GHB is short
(20–50 min), leading to a short time window of detection
(i.e., ≤ 4-5 h in blood, ≤ 12 h in urine) [1, 2, 5, 10, 11].
Currently, only relatively limited systematic and detailed
data are available on the acute toxicity of GHB that have
been collected in a standardized manner based on
emergency department (ED) presentations. The European
Monitoring Centre for Drugs and Drug Addiction
(EMCDDA) [12] collects and reports annually data on the
prevalence of drug use, including GHB. However, preva-
lence data do not provide information on the acute toxicity
of these substances. Surveys among GHB users [13, 14]
revealed that overdoses are common, especially among new
users. The most frequently reported reasons for use are
recreation and sexual enhancement. According to the Euro-
pean Drug Emergency Network (Euro-DEN), which col-
lected data on acute drug toxicity from 16 EDs in 10
European countries, GHB was among the top five drugs
recorded [15]. Data have also been collected from medical
stations during “rave” parties to investigate the time course
of awakening from GHB intoxication and the relationship
to plasma concentrations [16]. This case series illustrated
that patients with GHB intoxication had a Glasgow Coma
Scale (GCS) score ≤ 8 for a median time of 90 min (range,
30–105 min), followed by sudden recovery over ~30 min
(range, 10–50 min). The median GHB plasma concentra-
tion upon arrival was 212 μg/ml (range, 112–430 μg/ml),
and awakening was accompanied by a small change in
GHB concentrations. However, a confounding factor was
the co-use of other illicit drugs in 14 of the 15 cases. A
retrospective study of fatal GHB-related cases analyzed the
cause of death; however, in this study, 21 of the 23 cases
(91 %) had co-used other substances [17]. Data from
patients who presented to EDs with acute GHB toxicity
are also available [6, 7, 15, 18–24]. According to these
studies, GHB intoxication frequently results in coma, with
typically rapid spontaneous recovery. The typical patient
is young and male, and the co-use of alcohol and/or other
illicit substances is common. In terms of management,
some authors (e.g., [24]) have argued that conservative
management might be preferable to intubation. In one
study, agitation was more frequent when alcohol was co-
used. In contrast to what might be expected, the co-use of
cocaine and methylenedioxymethamphetamine (MDMA;
ecstasy) induced more pronounced and prolonged coma
[6]. A possible explanation for this observation could be
that higher amounts of GHB were used in these cases to
“calm down” [6]. GHB intoxication is associated with sub-
stantial morbidity [21].
However, systematic data over a longer period of time
are missing from the literature. Therefore, the present
study sought to describe the characteristics of GHB tox-
icity that resulted in presentation to a large urban ED in
Switzerland over a 14-year period (2002–2015). The pos-
sible moderation of GHB toxicity by the co-use of other
substances was also investigated. Specifically, we examined
possible associations between the co-use of other illicit
substances and/or alcohol and the severity of poisoning,
coma, agitation, the number of intubations, intensive care
unit (ICU) admission, and nausea/vomiting. We also ex-
amined possible associations between the co-use of stimu-
lants and the depth and duration of coma.
Methods
The study was approved by the ethics committee of
northwestern Switzerland (no. 163/08). We included all
cases that were related to GHB use who presented to
the ED of the University Hospital of Basel between
January 1, 2002, and September 30, 2015. The University
Hospital Basel is one of Switzerland's leading university
medical centers, serving as a primary care and referral
center for northwestern Switzerland. All emergency pa-
tients (50,000/year) are first evaluated by the ED.
Cases were retrieved from the electronic patient chart
database using a comprehensive full-text search algorithm
[25]. Briefly, the sensitive automatic search identified all
cases that mentioned GHB, GBL, or related terms (e.g.,
abbreviations and misspellings). Data abstraction was per-
formed by two of the authors of the study. The complete
patient charts of all of the retrieved cases were reviewed,
including notes by paramedics. All cases that were related
to GHB toxicity were included in the study. GHB use was
determined based on the patients’ self-reported use and/or
analytical confirmation. One case with typical clinical
findings and a bottle of GHB that was found in the
patient’s pocket was also included.
A retrospective study design was used with standardized
data recording [6, 15, 26]. Using full patient charts, we re-
corded age, sex, hour and day of the ED visit, heart rate,
diastolic and systolic blood pressure, GCS score, body
temperature, and laboratory test results. We also recorded
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any co-ingestion of alcohol or other drugs, both based on
self-report and/or the results of blood and urine toxicology
tests (when available). Coma was defined as GCS = 3-8
and/or documented coma. “Non-responsive coma” was de-
fined as GCS = 3. In comatose patients, recovery time was
defined as the time from initial presentation to paramedics
or the ED until the patient awoke, confirmed by a note in
the chart or GCS = 14 or 15. The term “polyintoxication”
refers to the reported co-use of other drugs and/or alcohol,
except as otherwise noted. The severity of poisoning was
assessed using the Poison Severity Score to grade acute poi-
soning [27]. Mild toxicity refers to mild, transient, and
spontaneously resolving symptoms. Moderate toxicity re-
fers to pronounced or prolonged symptoms. Severe toxicity
refers to severe or life-threatening symptoms [27].
Levels of GHB were determined using gas chromatog-
raphy–mass spectrometry and an enzymatic test assay (limit
of detection = 1.5 mg/L, limit of quantification = 5 mg/L).
Group differences were analyzed using χ2 tests (propor-
tions) or nonparametric Mann-Whitney U tests (mean
ranks). Spearman rank correlations were used to assess as-
sociations between variables. The data were analyzed using
Statistica 12 software (StatSoft, Tulsa, OK, USA). Values of
p < 0.05 were considered statistically significant.
Results
Number of admissions and patient characteristics
Over the 14 years of the study, from 2002 to 2015, we re-
corded 78 GHB-related intoxication cases in 60 different
patients. Six patients presented more than once to the ED
(two patients twice, one patient three times, one patient
four times, one patient six times, and one patient seven
times). The patient characteristics are shown in Table 1.
The mean ± SD age was 29.0 ± 8.0 years, and most of
the patients (71 %) were male. The majority of the patients
(64 %) had a documented and/or self-reported prior his-
tory of illicit substance use, including GHB in 41 cases
(53 %). Figure 1 shows the cases according to year.
Clinical findings
The clinical signs and symptoms of GHB toxicity are
shown in Table 2.
The most common cause for admission was coma (50
cases [64 %]), followed by agitation (18 cases [23 %]). A
GCS score of 3, indicating non-reactive coma, was re-
corded in 13 cases (17 %) at initial presentation and in
18 cases (23 %) at any time during observation. The ini-
tial GCS score negatively correlated with time to recov-
ery (Rs = -0.53, p < 0.001). Sudden recovery was reported
in 25 cases (32 %). The median time to regain con-
sciousness was 90 min (range, 3–400 min; Fig. 2).
Neurological symptoms other than central nervous
system depression included agitation (31 cases [40 %])
and clonus (16 cases [21 %]). An electrocardiogram was
performed in 27 cases (35 %), the significant findings of
which were sinus bradycardia in three cases, slow R-
progression in one case, ST-elevation in one case, and
T-wave elevation in one case. Computed tomography of
the head was performed in 18 cases (23 %), without sig-
nificant findings. Psychiatric assessment took place in 18
cases (23 %), and nine patients (12 %) had to be trans-
ferred to a psychiatric clinic (half of them according to
the psychiatric assessment and the other half without in-
volvement of a psychiatrist). Among the patients with a
GCS score of 3-8 and/or documented coma any time
during the observation (a total of 53 cases), 12 (23 %)
Table 1 Patient characteristics
Intoxications (n = 78) (%)
Age (years)
17-20 13 (17)
21-25 15 (19)
26-30 17 (22)
31-35 13 (17)
36-40 16 (21)
41-50 4 (5)
Prior history of illicit drug use 50 (64)
GHB 41 (53)
Cannabis 16 (21)
Opiates 13 (17)
Cocaine 14 (18)
MDMA (ecstasy)/other amphetamines 13 (17)
Time of presentation (arrival)
Night (8:00 PM–8:00 AM) 41 (53)
Weekend (Friday 5:00 PM–Monday
8:00 AM)
36 (46)
Monday–Friday (8:00 AM–8:00 PM) 24 (31)
Saturday–Sunday (8:00 AM–8:00 PM) 8 (10)
Monday–Thursday (8:00 PM–8:00 AM) 14 (18)
Friday–Sunday (8:00 PM–8:00 AM) 30 (38)
Weekday, time of arrival not recorded 2 (3)
Context of use
Recreational substance use 70 (90)
Accidental ingestion 3 (4)
Poisoning 3 (4)
Suicide attempt 2 (3)
Brought to emergency department by
Ambulance 62 (79)
Ambulance transport from a psychiatric
ward
5 (6)
Police 2 (3)
Other (friends, partner, etc.) 6 (8)
Unknown/not reported 3 (4)
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were admitted to the ICU and eight (15 %) were intu-
bated; computed tomography of the head was performed
in 14 (26 %) of these cases.
Use of other substances
In 36 cases (46 %), other illicit drugs were used in com-
bination with GHB according to the patients’ self-
reports (Table 3).
An ethanol test was performed in 66 cases (85 %).
Among these cases, a negative result was recorded in 43
cases. Among the 23 cases with positive ethanol tests, the
median alcohol concentration was 0.8 g/L (range, 0.1–
2.9 g/L). The toxicological test results for substances other
than GHB are shown in Table 3. Among the GHB monoin-
toxication cases (i.e., no other illicit drugs or alcohol
reported, n = 27), toxicological drug screening test results
were available in 23 cases. Among these 23 cases, 20 were
negative and three were positive for benzodiazepines. An
ethanol test was performed in all 20 of these cases, with no
self-reported co-use of other illicit drugs or alcohol and a
negative toxicological drug screening test. The ethanol test
was negative in 18 of the cases and positive in two of the
cases. Among the cases with self-reported co-use of other
illicit drugs (n = 36), toxicological drug screening test
results were available in 31 cases. Among these, five were
negative and 26 were positive. Among the positive tests, the
same substances as those that were self-reported were
detected in 21 cases. More substances than those that were
self-reported were detected with drug tests in four cases,
and fewer substances than those that were self-reported
were detected in one case.
Cases with analytical GHB confirmation
Confirmation of GHB was available in 37 cases (47 %), and
a quantitative analysis of GHB was available in 20 cases
(26 %). The median concentration was 240 mg/L (range,
8.3–373 mg/L). The characteristics of the 20 intoxications
with quantitative analysis of GHB are shown in Table 4.
Explanatory causes of severe intoxication
Coma was not significantly associated with polyintoxica-
tion. Coma occurred in 75 % (38/51) of the cases with
polyintoxication and 56 % (15/27) of the cases with mono-
intoxication (χ2 = 2.9, p = 0.09). Non-responsive coma
(GCS = 3) was present in 24 % (12/51) of the polyintoxica-
tions and 22 % (6/27) of the monointoxications (χ2 = 0.02,
p = 0.9). Coma occurred in 77 % (24/31) of the alcohol co-
users and 62 % (29/47) of the non-alcohol users (χ2 = 3.8, p
= 0.052). A GCS score of 3 was present in 35 % (11/31) of
the alcohol co-users and 38 % (18/47) of the non-alcohol
co-users (χ2 = 0.06, p = 0.8). The mean recovery time in
comatose patients (GCS = 3-8 and/or documented coma)
was 142 min (n = 22; range, 20–400 min) in patients with
co-use of alcohol compared with 89 min (n = 23; range,
3–300 min) in patients without alcohol co-use (Z = 1.8, p =
0.07). Severely intoxicated patients used other substances
(alcohol and/or other illicit drugs) in addition to GHB
(polyintoxications) in 70 % (39/56) of the cases, and non-
severely intoxicated patients used additional substances in
55 % (12/22) of the cases (χ2 = 1.6, p = 0.2). The co-use of
alcohol (self-reported and/or laboratory-detected; n = 31)
was documented in 46 % (26/56) of the severely intoxi-
cated patients and 23 % (5/22) of the non-severely intoxi-
cated patients (χ2 = 3.7, p = 0.054). Agitation was not more
frequent among patients with poly- vs. monointoxications
or in patients with or without the co-use of alcohol.
Polyintoxications or alcohol co-use were not associated
with the number of intubations or ICU admissions.
Reported and/or laboratory-confirmed alcohol co-use was
not significantly associated with nausea/vomiting (5/31 vs.
2/47; χ2 = 3.2, p = 0.07). The co-use of stimulants (e.g.,
cocaine, amphetamine, and MDMA) was not significantly
associated with non-responsive coma (GCS = 3; 3/15 vs.
15/51, χ2 = 0.5, p = 0.5) or mean recovery time (n = 11;
93 min [range, 10–270 min] vs. 126 min [range, 3–
400 min]; N = 30, Z = 0.77, p = 0.4).
Discussion
This retrospective study described the characteristics of
GHB toxicity in patients who presented to a large ED in
Switzerland. The typical patient was approximately
30 years old and male, had a history of previous illicit
substance use, currently used GHB for recreational pur-
poses (often in combination with alcohol [one-third of
Fig. 1 Annual incidence of cases of GHB intoxication
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cases] and/or other recreational substances [nearly half
of cases], most commonly cannabis and cocaine), and
was brought to the ED by ambulance at night. The most
common causes of admission were coma and agitation.
Although impaired consciousness led to characterization
of the intoxication as severe in the majority of the cases,
sudden recovery was recorded in one-third of the cases,
and the majority of the patients were discharged home
directly from the ED. No significant association was
found between polyintoxication and coma, between the
co-use of alcohol and the severity of poisoning, or be-
tween the co-use of alcohol or other illicit substances
and agitation, intubation, degree of coma, or ICU admis-
sion. However, nearly significant (all p = 0.05–0.07) asso-
ciations were found between alcohol co-use and coma
frequency, coma duration, nausea/vomiting, and overall
severity of intoxication, which were likely clinically rele-
vant. In both the present study and a previous retro-
spective case-study from Zurich, Switzerland [6], alcohol
co-use was not significantly associated with the level of
consciousness (i.e., decreased GCS score). In contrast to
the study from Zurich, however, we found no significant
association between the co-use of alcohol and agitation
or nausea/vomiting [6]. We also could not confirm the
previous finding of deeper (i.e., non-responsive) and
more prolonged coma in co-users of stimulant drugs [6].
Other retrospective case-series with data from ED pa-
tients [7, 15, 19, 20, 23] also confirmed the characteris-
tics of typical GHB intoxication, particularly the co-use
of alcohol and/or other illicit substances with typically
rapid spontaneous recovery (usually within ~2 h of pres-
entation; maximum of 6.5 h after presentation). Because
Table 2 Characteristics of GHB intoxication
Intoxications (n = 78) (%)
Cause of admission
Coma (GCS = 3-8 and/or documented
coma)
50 (64)
Agitation/aggression 18 (23)
Collapse/syncope 7 (9)
Convulsions/seizures 6 (8)
Confusion 2 (3)
Dizziness 2 (3)
Anxiety 1 (1)
Nausea 1 (1)
Delirium 1 (1)
Suspected intoxication 1 (1)
Hyperventilation 1 (1)
GHB identification
Self-report 40 (51)
Toxicological analysis 24 (31)
Self-report and toxicological analysis 13 (17)
GHB bottle in pocket 1 (1)
Initial Glasgow Coma Scale score
3 13 (17)
4-8 16 (21)
9-12 17 (22)
13-15 22 (28)
Unknown 10 (13)
Lowest Glasgow Coma Scale score
3 18 (23)
4-8 17 (22)
9-12 11 (14)
13-15 20 (26)
Unknown 12 (15)
Clinical findings any time prior or during presentation to the emergency
department
Coma (GCS = 3-8 and/or documented
coma)
53 (68)
Agitation 31 (40)
Hypotension (systolic blood pressure
< 95 mmHg)
19 (24)
Clonus 16 (21)
Bradycardia (<60 beats/min) 12 (15)
Hypothermia (< 36 °C) 7 (9)
Respiratory insufficiency (oxygen saturation
< 92 %)
7 (9)
Nausea/vomiting 7 (9)
Urine or stool incontinence 4 (5)
Management
Monitoring 64 (82)
Table 2 Characteristics of GHB intoxication (Continued)
Intravenous fluids 32 (41)
Oxygen administration 24 (31)
Intubation 8 (10)
Urinary catheterization 3 (4)
External heating 2 (3)
Medication
Benzodiazepines 10 (13)
Naloxone 8 (10)
Flumazenil 1 (1)
Severity of poisoning (based on Poison Severity Score [27])
Minor 5 (6)
Moderate 17 (22)
Severe 56 (72)
Discharge from emergency department
To home 56 (72)
To intensive care unit 13 (17)
To psychiatric clinic 9 (12)
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of this rapid recovery, some authors have indicated that
intubation may not always be necessary in cases of GHB-
induced coma [7]. In more recent studies [24], conserva-
tive airway management (i.e., no intubation) appears to be
preferable in many cases because intubation is associated
with a longer stay in the ED. In the present study, only
15 % of the patients with coma were intubated, and only
~25 % were admitted to the ICU and/or underwent com-
puted tomography of the head. However, because of the
frequent co-use of other substances and because the
analytical detection of GHB is not routinely performed,
general recommendations regarding the need for intub-
ation should be made with caution. In a study from Spain
[19], polyintoxication was associated with more severe
symptoms. In the same study, a decreasing trend in the
number of intoxications was observed in the last 3 years
of the study (i.e., 2005–2007). In the present study,
most of the GHB-related admissions were recorded
between 2007 and 2009. Although no fatalities were
reported in our study and in most of the previous ED
studies [6, 7, 19, 20, 23], fatalities were reported in
case series from Sweden (e.g., a young female patient with
severe brain anoxia, deeply comatose on arrival) [21] and
the United Kingdom (e.g., 25-year-old male with hypoxic
brain injury and cardiorespiratory arrest on arrival, with
the cause of death listed as “mixed drug overdose
[MDMA and GHB toxicity]”) [22]. However, deaths that
may have occurred before admission to the ED of our hos-
pital cannot be excluded.
Antidotes that are available for other substance groups
(e.g., naloxone and flumazenil) have no beneficial effect in
the treatment of GHB intoxication. For example, the
duration of coma does not significantly vary with the use of
such antidotes [1, 19]. Currently, the management of GHB
toxicity is primarily supportive. However, benzodiazepines
appear to be a therapeutic option in cases of GHB with-
drawal symptoms (e.g., anxiety, insomnia, tremor, tachycar-
dia, agitation, delirium, and hallucinations), which may
occur after long-term abuse, beginning within 1–6 h after
taking the last dose [1]. Barbiturates (e.g., phenobarbital),
baclofen, or propofol may also be considered treatments,
particularly in cases of benzodiazepine-refractory GHB
withdrawal [2, 28–30]. Specifically for non-responsive
hallucinations, antipsychotics may also be indicated [30].
One concern is the use of GHB to “spike” a person’s
drink to engage in non-consensual sexual activity or fa-
cilitate other criminal actions, such as robbery [31, 32].
Fig. 2 Time to regain consciousness (in minutes)
Table 3 Concomitant substance use
Intoxications (n = 78) (%)
Concomitant substance use
GHB monointoxication (no other illicit
drugs or alcohol reported)
27 (35)
GHB polyintoxication (reported co-use
of other drugs and/or alcohol)
51 (65)
Reported co-use of alcohol 26 (33)
Reported and/or laboratory-confirmed
co-use of alcohol
31 (40)
Co-use of other illicit drugs (according to
patient self-report)
36 (46)
Cannabis 14 (18)
Cocaine 13 (17)
Sedatives 12 (15)
Opiates 8 (10)
Amphetamine 4 (5)
MDMA (ecstasy) 4 (5)
Ketamine 1 (1)
Laboratory test data 70 (90)
Ethanol test performed 66 (85)
Positive ethanol test 23 (29)
Drug test performed 67 (86)
Positive for benzodiazepines 15 (19)
Positive for cannabis 13 (17)
Positive for cocaine 10 (13)
Positive for methadone 4 (5)
Positive for opiates 2 (3)
Positive for amphetamines 1 (1)
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In our study, use for recreational purposes was reported
in the large majority of cases (90 %), but three cases
were reported as “poisoning,” in which GHB may have
been given to facilitate sexual assault. Three cases were
recorded as “accidental use,” in which the patients re-
ported not knowing what substance they consumed
(n.b., GHB was analytically confirmed). Some of the
cases might have been related to abuse but not reported
as such. However, accidental ingestion, sometimes lethal,
has been reported, including cases of mistaking GHB for
water or accidental ingestion by children [33].
One strength of our study is the quantitative analysis
of GHB in blood, which was available in one-fourth of
the cases, and qualitative substance confirmation, which
was available in nearly half of the cases. Previously pub-
lished series were mainly based only on self-reported
GHB use. With a qualitative analysis that was available
in 37 cases and additional quantitative analysis that was
available in 20 cases, our study may be considered one
of the relatively large compilations of analytically proven
nonfatal cases. Controlled administration of oral psycho-
active doses of GHB of 20-72 mg/kg, which did not pro-
duce loss of consciousness, resulted in average maximal
plasma levels of 22-130 mg/L [5, 34]. Toxicological ana-
lysis in nonfatal cases showed a mean GHB concentra-
tion of 245 mg/L (range, 86–551 mg/L; n = 20) in one
small study [35], a median GHB concentration of
180 mg/L (range, 45–295 mg/L; n = 15) in another study
[36], and a mean GHB concentration of 137 mg/L (me-
dian, 103 mg/L; range, 29–490 mg/L; n = 54) in a larger
study [18]. Published reports of GHB-related fatalities
show a wide range of concentrations that are measured
in postmortem blood (0-6500 mg/L) [17, 33, 37, 38],
with a median concentration of 190–347 mg/L [17, 33,
37], mean ± SD concentration of 482 ± 758 mg/L [38],
and concentration of 300 mg/L that is suggested to be
sufficient to cause death [37]. Thus, the concentrations
of GHB in survivors and non-survivors seem to overlap.
However, the possible production and redistribution of
GHB after death (depending on the methodology, con-
centrations up to 197 mg/L even in cases without GHB
ingestion [38]) and several other factors (e.g., elapsed
time from ingestion to death and from death to sample
collection and testing; methods of sample storage and
analysis; different levels based on sampling site; the oc-
currence of delayed death at low GHB concentrations
because of loss of consciousness, hypoventilation, and
hypoxia [1, 33, 38]; and the possibility that other sub-
stances are the cause of death in polyintoxication cases)
make the interpretation of postmortem GHB concentra-
tions difficult, with no clearly defined “lethal” concentra-
tion [33]. The measured concentrations in our study
(median, 240 mg/L; range, 8.3–373 mg/L) were similar
to those reported in the other non-fatal GHB intoxication
Table 4 Characteristics of GHB intoxications with quantitative analysis of GHB (n = 20)
Gender Age Other substances reported and/or
analytically confirmed
Severity of poisoning GHB concentration in
blood
Male 37 Benzodiazepines, cocaine Moderate 8.3 mg/L
Male 23 Cannabis, cocaine Severe 309 mg/L
Female 19 Alcohol, cannabis Severe 31 mg/L
Male 20 Alcohol Moderate 29 mg/L
Female 22 Alcohol Severe 95 mg/L
Male 35 Alcohol Severe 59 mg/L
Male 47 Alcohol, cannabis, methadone Severe 83 mg/L
Female 19 — Severe 259 mg/L (82 mg/L in urine)
Female 17 — Moderate 62 mg/L
Male 39 Benzodiazepines Severe 331 mg/L
Female 25 — Minor 108 mg/L
Male 39 — Severe 327 mg/L
Male 39 — Severe 360 mg/L
Male 27 Opiates Minor > 20 mg/L
Male 27 — Moderate 373 mg/L
Male 17 — Severe 301 mg/L
Male 21 Alcohol, cannabis Severe 86 mg/L
Female 29 Alcohol, cocaine Severe 313 mg/L
Male 25 Alcohol, cocaine Severe 307 mg/L
Female 24 Cocaine Severe 240 mg/L
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cases. Blood concentrations > 300 mg/L appear to be asso-
ciated with severe intoxication (Table 4). However, the
co-use of other substances can affect symptoms and thus
the severity of poisoning. Even in cases of monointoxica-
tion, the exact time of use is not always known, and no
definitive conclusions can be drawn regarding the associ-
ation between GHB concentration and severity. This may
also explain the cases of severe intoxication with only low
GHB concentrations detected.
Our study has limitations. Although the full-text
search of the electronic patient charts likely allowed the
retrieval of all cases, cases of GHB use but with no self-
reported use by the patient and no physician-suspected
substance use may not have been recognized and there-
fore not included in the study. Moreover, polyintoxica-
tion was common, and some of the reported signs and
symptoms may be attributable to the use of substances
other than GHB. Nevertheless, these limitations are
common in all retrospective studies that investigate the
acute toxicity of psychoactive substances. The short half-
life of elimination of GHB may also have led to un-
detected levels despite laboratory analysis in some cases,
whereas substances that are taken as co-medication or
given as treatments by paramedics (e.g., benzodiaze-
pines) or can be detected in samples beyond acute in-
toxication (e.g., cannabis) may be overrepresented in the
analytical results. Furthermore, some data were missing
in the patient histories. Clinical data were not always re-
corded in a standardized manner at presentation, sug-
gesting the possibility of reporting bias (e.g., sudden
recovery that was reported in 32 % of the cases may be
underrepresented because some clinicians may not have
mentioned this in the clinical records). Furthermore,
analytical confirmation was not available in all of the
cases. Lastly, data from only one ED may not be repre-
sentative because it may reflect only local trends.
Conclusion
In conclusion, GHB intoxication resulted in impaired
consciousness as a typical finding, with rapid spontan-
eous recovery in many cases. The co-use of ethanol and/
or other illicit substances was common. Future studies
that quantitatively analyze more GHB monointoxication
cases could help elucidate the relationship between clin-
ical presentation and laboratory results and also define a
crucial concentration limit.
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